Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Original article  

PARP as disease target: endotoxic shock

P. Radermacher

Med Sci Monit 2003; 9(1): 58-0 :: ID: 15197

Abstract

The activation of PARP is attributed a crucial role in the development of multiple organ failure induced by endotoxemia, sepsis and septic shock, in particular as a result of compromised vascular contractility [1] and endothelial vasorelaxation [2], impaired mitochondrial respiration [3], and pulmonary as well as intestinal hyperpermeability [4]. Therefore, the therapeutic potential of PARP-inhibition has been investigated in endotoxic shock using nicotinamide, 3-aminobenzamide and phenantridinones. Nicotinamide, which was originally tested as a substrate supplement already 30 years ago [5], not only to is a (weak) PARP-inhibitor but also reduced NO [6, 7] and cytokine formation [8]. Results are controversial in vivo: while it stabilized hemodynamics, attenuated acute lung injury and ultimately improved survival in some studies [9,10], it failed to prevent lactic acidosis and renal or hepatic injury in others [11]. In our long term model of hyperdynamic porcine endotoxemia which is characterized by a sustained increase in cardiac output and thus mimicks the clinical scenario of human septic shock, nicotinamide did not have any beneficial effect on the endotoxin-induced metabolic disturbances [12]. 3-aminobenzamide, the ‘classical’ PARP-inhibitor used in endotoxic shock models, not only attenuated the LPS-induced vascular failure in vitro, but also reduced the pulmonary and intestinal microvascular injury and thus improved the mucosal barrier function [4, 13]. Nevertheless, in other models 3-aminobenzamide also failed to prevent visceral organ dysfunction [11], and in short term porcine endotoxemia it did not influence the LPS-induced effects on the systemic and pulmonary hemodynamics [14]. Most recently, the novel and highly PARP-1-selective phenanthridinones [15] were reported to prevent vascular failure and acute lung injury in rat endotoxic shock [16]. Moreover, used as a pretreatment, they preserved myocardial contractility both in endotoxin-injected rats [17] and porcine polymicrobial peritonitis [18]. Finally, in our endotoxmic swine model they improved stroke volume and blunted the otherwise progressive intestinal mucosal acidosis [19]. Taken together, nicotinamide showed controversial efficacy in the treatment of endotoxic shock, probably due to its relatively poor activity as a PARP-inhibitor and due to the potential hepatotoxicity when administered in high doses. By contrast, the currently available data study support the hypothesis that potent and selective PARP inhibitors may be of beneficial and therapeutic value in septic shock.

Keywords: endotoxin, Sepsis, nicotinamide, 3-aminobenzamide, phenanthridinone PARS inhibitors, rodent, Swine

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

26 Feb 2024 : Clinical Research  

Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...

Med Sci Monit In Press; DOI: 10.12659/MSM.942509  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750